ImmunoGen Inc (NASDAQ:IMGN)

During the Trading Day
7.62 -0.25 / -3.18%
As of 3:59pm ET
Day’s Change
During After-Hours   Switch to standard view »
7.60 -0.02 / -0.26%
 
Volume: 19.3K
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$677.7M

Company Description

ImmunoGen, Inc. is a biotechnology company, which develops novel anticancer therapeutics using its antibody-drug conjugate technology. It also have developed engineered linkers that keep the payload firmly attached to the antibody while the whole therapy is circulating through the bloodstream and then release it once the therapy has reached and entered a cancer cell. The company also uses antibody-drug conjugate targeted antibody payload technology together with strong antibody expertise to develop its own product candidates. ImmunoGen was founded in March 1981 and is headquartered in Waltham, MA.

Contact Information

ImmunoGen, Inc.
830 Winter Street
Waltham Massachusetts 02451-1477
P:(781) 895-0600
Investor Relations:

Employees

Shareholders

Mutual fund holders55.00%
Other institutional32.07%
Individual stakeholders1.09%

Top Executives

Daniel M. JuniusPresident, Chief Executive Officer & Director
David B. JohnstonChief Financial Officer & Executive Vice President
Sandra E. PooleSenior Vice President-Technical Operations
Richard J. GregoryChief Scientific Officer & Executive VP-Research
John M. LambertExecutive Vice President

To view my watchlist

Not a member yet?

Sign up now for a free account